Pfizergan Would Have Challenged Novartis For 2015 Approvals Crown
Novartis had the most new molecular entity approvals in 2015 with four, all developed in house; next in line is Allergan, with three approvals that stem from acquisitions and licensing.
You may also be interested in...
No company received more than two approvals among the 28 novel agents approved in 2016 by US FDA's drug and biologics centers combined.
Rigorous planning and a multidisciplinary team including database experts and healthcare specialists with local knowledge are vital to effective real-world evidence, white paper shows.
The latest submission and expedited review program news and highlights from our US FDA Performance Tracker.